|
1
|
Baselga J and Swain SM: Novel anticancer
targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lipton A, Goodman L, Leitzel K, Cook J,
Sperinde J, Haddad M, Köstler WJ, Huang W, Weidler JM, Ali S, et
al: HER3, p95HER2, and HER2 protein expression levels define
multiple subtypes of HER2-positive metastatic breast cancer. Breast
Cancer Res Treat. 141:43–53. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aurisicchio L, Marra E, Roscilli G,
Mancini R and Ciliberto G: The promise of anti-ErbB3 monoclonals as
new cancer therapeutics. Oncotarget. 3:744–758. 2012.PubMed/NCBI
|
|
4
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sergina NV, Rausch M, Wang D, Blair J,
Hann B, Shokat KM and Moasser MM: Escape from HER-family tyrosine
kinase inhibitor therapy by the kinase-inactive HER3. Nature.
445:437–441. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kruser TJ and Wheeler DL: Mechanisms of
resistance to HER family targeting antibodies. Exp Cell Res.
316:1083–1100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hamburger AW: The role of ErbB3 and its
binding partners in breast cancer progression and resistance to
hormone and tyrosine kinase directed therapies. J Mammary Gland
Biol Neoplasia. 13:225–233. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu Y, Zhang Y, Wang M, Li Q, Qu Z, Shi V,
Kraft P, Kim S, Gao Y, Pak J, et al: Downregulation of HER3 by a
novel antisense oligonucleotide, EZN-3920, improves the antitumor
activity of EGFR and HER2 tyrosine kinase inhibitors in animal
models. Mol Cancer Ther. 12:427–437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Malm M, Kronqvist N, Lindberg H,
Gudmundsdotter L, Bass T, Frejd FY, Höidén-Guthenberg I, Varasteh
Z, Orlova A, Tolmachev V, et al: Inhibiting HER3-mediated tumor
cell growth with affibody molecules engineered to low picomolar
affinity by position-directed error-prone PCR-like diversification.
PLoS One. 8:e627912013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Terwisscha van Scheltinga AG, Lub-de Hooge
MN, Abiraj K, Schröder CP, Pot L, Bossenmaier B, Thomas M,
Hölzlwimmer G, Friess T, Kosterink JG, et al: ImmunoPET and
biodistribution with human epidermal growth factor receptor 3
targeting antibody 89Zr-RG7116. MAbs. 6:1051–1058. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wehrenberg-Klee E, Turker NS, Chang B,
Heidari P and Mahmood U: Development of a HER3 PET probe for breast
cancer imaging. J Nucl Med. 55(Suppl 1): s5502014.
|
|
12
|
Wester HJ and Kessler H: Molecular
targeting with peptides or peptide-polymer conjugates: Just a
question of size? J Nucl Med. 46:1940–1945. 2005.PubMed/NCBI
|
|
13
|
Orlova A, Malm M, Rosestedt M, Varasteh Z,
Andersson K, Selvaraju RK, Altai M, Honarvar H, Strand J, Ståhl S,
et al: Imaging of HER3-expressing xenografts in mice using a
99mTc(CO)3-HEHEHE-ZHER3:08699
affibody molecule. Eur J Nucl Med Mol Imaging. 41:1450–1459. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Löfblom J, Feldwisch J, Tolmachev V,
Carlsson J, Ståhl S and Frejd FY: Affibody molecules: Engineered
proteins for therapeutic, diagnostic and biotechnological
applications. FEBS Lett. 584:2670–2680. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baum RP, Prasad V, Müller D, Schuchardt C,
Orlova A, Wennborg A, Tolmachev V and Feldwisch J: Molecular
imaging of HER2-expressing malignant tumors in breast cancer
patients using synthetic 111In- or
68Ga-labeled affibody molecules. J Nucl Med. 51:892–897.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sörensen J, Sandberg D, Sandström M,
Wennborg A, Feldwisch J, Tolmachev V, Åström G, Lubberink M,
Garske-Román U, Carlsson J, et al: First-in-human molecular imaging
of HER2 expression in breast cancer metastases using the
111In-ABY-025 affibody molecule. J Nucl Med. 55:730–735.
2014. View Article : Google Scholar
|
|
17
|
Tolmachev V, Altai M, Sandström M, Perols
A, Karlström AE, Boschetti F and Orlova A: Evaluation of a
maleimido derivative of NOTA for site-specific labeling of affibody
molecules. Bioconjug Chem. 22:894–902. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ahlgren S, Orlova A, Rosik D, Sandström M,
Sjöberg A, Baastrup B, Widmark O, Fant G, Feldwisch J and Tolmachev
V: Evaluation of maleimide derivative of DOTA for site-specific
labeling of recombinant affibody molecules. Bioconjug Chem.
19:235–243. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hofstrom C, Orlova A, Altai M, Wangsell F,
Graslund T and Tolmachev V: Use of a HEHEHE purification tag
instead of a hexahistidine tag improves biodistribution of affibody
molecules site-specifically labeled with 99mTc,
111In, and 125I. J Med Chem. 54:3817–3826.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tolmachev V, Tran TA, Rosik D, Sjöberg A,
Abrahmsén L and Orlova A: Tumor targeting using affibody molecules:
Interplay of affinity, target expression level, and binding site
composition. J Nucl Med. 53:953–960. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Orlova A, Hofström C, Strand J, Varasteh
Z, Sandstrom M, Andersson K, Tolmachev V and Gräslund T:
[99mTc(CO)3]+-(HE)3-ZIGF1R:4551,
a new Affibody conjugate for visualization of insulin-like growth
factor-1 receptor expression in malignant tumours. Eur J Nucl Med
Mol Imaging. 40:439–449. 2013. View Article : Google Scholar
|
|
22
|
Heskamp S, Laverman P, Rosik D, Boschetti
F, van der Graaf WT, Oyen WJ, van Laarhoven HW, Tolmachev V and
Boerman OC: Imaging of human epidermal growth factor receptor type
2 expression with 18F-labeled affibody molecule
ZHER2:2395 in a mouse model for ovarian cancer. J Nucl
Med. 53:146–153. 2012. View Article : Google Scholar
|
|
23
|
Björke H and Andersson K: Measuring the
affinity of a radio-ligand with its receptor using a rotating cell
dish with in situ reference area. Appl Radiat Isot. 64:32–37. 2006.
View Article : Google Scholar
|
|
24
|
Wållberg H and Orlova A: Slow
internalization of anti-HER2 synthetic affibody monomer
111In-DOTA-ZHER2:342-pep2: implications for
development of labeled tracers. Cancer Biother Radiopharm.
23:435–442. 2008. View Article : Google Scholar
|
|
25
|
Razumienko EJ, Scollard DA and Reilly RM:
Small-animal SPECT/CT of HER2 and HER3 expression in tumor
xenografts in athymic mice using trastuzumab Fab-heregulin
bispecific radioimmunoconjugates. J Nucl Med. 53:1943–1950. 2012.
View Article : Google Scholar : PubMed/NCBI
|
